Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi

Thindwa, D., MacPherson, P. , Choko, A. T., Khundi, M., Sambakunsi, R., Ngwira, L. G., Kalua, T., Webb, E. L. and Corbett, E. L. (2018) Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. International Journal of Tuberculosis and Lung Disease, 22(3), pp. 273-279. (doi: 10.5588/ijtld.17.0370) (PMID:29471904) (PMCID:PMC5824849)

[img] Text
300612.pdf - Published Version
Available under License Creative Commons Attribution.

218kB

Abstract

SETTING: Despite worldwide scale-up of human immunodeficiency virus (HIV) care services, relatively few countries have implemented isoniazid preventive therapy (IPT). Among other programmatic concerns, IPT completion tends to be low, especially when not fully integrated into HIV care clinics. OBJECTIVE: To estimate non-completion of 6-month IPT and its predictors among HIV-positive adults aged ≥ 16 years. DESIGN: A prospective cohort study nested within a cluster-randomised trial of TB prevention was conducted between February 2012 and June 2014. IPT for 6 months was provided with pyridoxine at study clinics. Non-completion was defined as loss to follow-up (LTFU), death, active/presumptive TB or stopping IPT for any other reason. Random-effects logistic regression was used to determine predictors of non-completion. RESULTS: Of 1284 HIV-positive adults initiated on IPT, 885/1280 (69.1%) were female; the median CD4 count was 337 cells/μl (IQR 199–511); 320 (24.9%) did not complete IPT. After controlling for antiretroviral treatment status, IPT initiation year, age and sex, non-completion of IPT was associated with World Health Organization stage 3/4 (aOR 1.76, 95%CI 1.22–2.55), CD4 count 100–349 cells/μl (aOR 1.93, 95%CI 1.10–3.38) and any reported side effects (aOR 22.00, 95%CI 9.45–46.71). CONCLUSION: Completion of IPT was suboptimal. Interventions to further improve retention should target immunosuppressed HIV-positive adults and address side effects.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:MacPherson, Professor Peter
Authors: Thindwa, D., MacPherson, P., Choko, A. T., Khundi, M., Sambakunsi, R., Ngwira, L. G., Kalua, T., Webb, E. L., and Corbett, E. L.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Public Health
Journal Name:International Journal of Tuberculosis and Lung Disease
Publisher:International Union against Tuberculosis and Lung Disease
ISSN:1027-3719
ISSN (Online):1815-7920
Copyright Holders:Copyright © 2018 Thindwa et al.
First Published:First published in International Journal of Tuberculosis and Lung Disease 22(3):273-279
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record